Your request to link to rcsb for PD-1/PD-L1
- 3BIK: crystal structure of the pd-1/pd-l1 complex (10.1073/PNAS.0712278105 )
- 3BIS: crystal structure of the pd-l1 (10.1073/PNAS.0712278105 )
- 3FN3: dimeric structure of pd-l1 (10.1007/S13238-010-0022-1 )
- 3SBW: crystal structure of the complex between the extracellular domains of mouse pd-1 mutant and human pd-l1
- 4Z18: crystal structure of human pd-l1
- 4ZQK: structure of the complex of human programmed death-1 (pd-1) and its ligand pd-l1. (10.1016/J.STR.2015.09.010 )
- 5C3T: pd-1 binding domain from human pd-l1 (10.1016/J.STR.2015.09.010 )
- 5GGT: pd-l1 in complex with bms-936559 fab (10.1038/NCOMMS13354 )
- 5GRJ: crystal structure of human pd-l1 with monoclonal antibody avelumab (10.1038/CR.2016.102 )
- 5IUS: crystal structure of human pd-l1 in complex with high affinity pd-1 mutant (10.1016/J.STR.2016.06.026 )
- 5J89: structure of human programmed cell death 1 ligand 1 (pd-l1) with low molecular mass inhibitor (10.18632/ONCOTARGET.8730 )
- 5J8O: structure of human programmed cell death 1 ligand 1 (pd-l1) with low molecular mass inhibitor (10.18632/ONCOTARGET.8730 )
- 5JDR: structure of pd-l1 (10.1038/CELLDISC.2017.4 )
- 5JDS: crystal structure of pd-l1 complexed with a nanobody at 1.7 angstron resolution (10.1038/CELLDISC.2017.4 )
- 5N2D: structure of pd-l1/small-molecule inhibitor complex (10.1021/ACS.JMEDCHEM.7B00293 )
- 5N2F: structure of pd-l1/small-molecule inhibitor complex (10.1021/ACS.JMEDCHEM.7B00293 )
- 5NIU: structure of human programmed cell death 1 ligand 1 (pd-l1) with low molecular mass inhibitor (10.18632/ONCOTARGET.20050 )
- 5O45: structure of human pd-l1 in complex with inhibitor (10.1002/ANIE.201707707 )
- 5O4Y: structure of human pd-l1 in complex with inhibitor (10.1002/ANIE.201707707 )
- 5X8L: pd-l1 in complex with atezolizumab (10.1038/S41598-017-06002-8 )
- 5X8M: pd-l1 in complex with durvalumab (10.1038/S41598-017-06002-8 )
- 5XJ4: complex structure of durvalumab-scfv/pd-l1 (10.1007/S13238-017-0412-8 )
- 5XXY: crystal structure of pd-l1 complexed with atezolizumab fab at 2.9a (10.18632/ONCOTARGET.21652 )
- 6HIG: hpd-1/nbo1a fab complex (10.1084/JEM.20182359 )
- 6JBT: complex structure of toripalimab-fab and pd-1 (10.1080/19420862.2019.1596513 )
- 6JJP: crystal structure of fab of a pd-1 monoclonal antibody mw11-h317 in complex with pd-1 (10.1038/S42003-019-0642-9 )
- 6NM7: pd-l1 igv domain bound to fragment (10.1016/J.BMCL.2019.01.028 )
- 6NM8: igv-v76t bms compound 105 (10.1016/J.BMCL.2019.01.028 )
- 6NNV: pd-l1 igv domain complex with macro-cyclic peptide (10.1016/J.BMCL.2019.01.028 )
- 6NOJ: pd-l1 igv domain v76t with fragment (10.1016/J.BMCL.2019.01.028 )
- 6NOS: pd-l1 igv domain v76t with fragment (10.1016/J.BMCL.2019.01.028 )
- 6NP9: pd-l1 igv domain v76t with fragment (10.1016/J.BMCL.2019.01.028 )
- 6PV9: human pd-l1 bound to a macrocyclic peptide which blocks the pd-1/pd-l1 interaction (10.1021/ACS.BIOCHEM.9B00822 )
- 6R3K: structure of human programmed cell death 1 ligand 1 (pd-l1) with low molecular mass inhibitor
- 6RPG: structure of human programmed cell death 1 ligand 1 (pd-l1) with inhibitor (10.1021/ACS.JMEDCHEM.9B00795 )
- 6UMT: high-affinity human pd-1 pd-l2 complex (10.1073/PNAS.1916916116 )
- 6UMU: human apo pd-1 triple mutant (10.1073/PNAS.1916916116 )
- 6UMV: human apo pd-1 double mutant (10.1073/PNAS.1916916116 )
- 6VQN: co-crystal structure of human pd-l1 complexed with compound a (10.1038/S41467-021-21410-1 )
- 6XKR: structure of sasanlimab fab in complex with pd-1 (10.1158/1535-7163.MCT-20-0093 )
- 6YCR: structure of human pd-l1 in complex with inhibitor (10.1002/ADTP.202000195 )
- 7BEA: structure of human programmed cell death 1 ligand 1 (pd-l1) with inhibitor (10.1021/ACSMEDCHEMLETT.1C00033 )
- 7BXA: crystal structure of pd-1 in complex with tislelizumab fab (10.1016/J.BBRC.2020.04.121 )
- 7C88: complex structure of js003 and pd-l1 (10.1038/S41392-020-00254-Z )
- 7CGW: complex structure of pd-1 and tislelizumab fab (10.1002/2211-5463.13102 )
- 7CU5: n-glycosylation of pd-1 and glycosylation dependent binding of pd-1 specific monoclonal antibody camrelizumab (10.15252/EMBR.202051444 )
- 7CZD: crystal structure of pd-l1 in complex with a vhh (10.1136/JITC-2020-002131 )
- 7E9B: structural basis of hlx10 pd-1 receptor recognition, a promising anti- pd-1 antibody clinical candidate for cancer immunotherapy
- 7NLD: structure of human programmed cell death 1 ligand 1 (pd-l1) with low molecular mass inhibitor (10.1021/ACS.JMEDCHEM.1C00957 )
- 7OUN: structure of human pd-l1 in complex with macrocyclic inhibitor (10.3390/MOLECULES26164848 )